Evidence map›Paper›PMID 28822614›Full record

ArticleMolecular genetics and metabolism2018

Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.

Jonathan C P Roos, Matthew J Daniels, Elizabeth Morris, Hanna I Hyry, Timothy M Cox

Open access · greenAbstract readCase Reports
In one paragraph

Article in Molecular genetics and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Altered Splicing ofMedicina (Kaunas, Lithuania) · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Comment: Why are females with Fabry disease affected?Molecular genetics and metabolism reports · 2019
    Article
  8. Article
  9. A Nationwide Survey on Danon Disease in Japan.International journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jonathan C P RoosDepartment of Medicine, University of Cambridge, Cambridge, UK.
Matthew J DanielsDepartment of Medicine, University of Cambridge, Cambridge, UK.
Elizabeth MorrisDepartment of Medicine, University of Cambridge, Cambridge, UK.
Hanna I HyryDepartment of Medicine, University of Cambridge, Cambridge, UK.
Timothy M CoxDepartment of Medicine, University of Cambridge, Cambridge, UK. Electronic address: tmc12@medschl.cam.ac.uk.
University of Cambridge · GB

Funding

Department of HealthMedical Research Council MR/K025570/1Wellcome Trust 098519
6 · The paper itself

Abstract

backgroundDanon disease is an X-linked disturbance of autophagy manifesting with cognitive impairment and disordered heart and skeletal muscle. After a period of relative stability, patients deteriorate rapidly and may quickly become ineligible for elective heart transplantation - the only life-saving therapy.

methodsWe report a large pedigree with diverse manifestations of Danon disease in hemizygotes and female heterozygotes.

resultsMalignant cardiac arrhythmias requiring amiodarone treatment induced thyroid disease in two patients; intractable thyrotoxicosis, which enhances autophagy, caused the death of a 21year-old man. Our patients also had striking elevation of serum troponin I during the accelerated phase of their illness (p<0.01) and rising concentrations heralded cardiac decompensation. We argue for changes to cardiac transplantation eligibility criteria.

conclusionDanon disease causes hypertrophic cardiomyopathy - here we propose a common pathophysiological basis for the metabolic and structural effects of this descriptive class of heart disorders. We also contend that troponin I may have prognostic value and merits exploration for clinical decision-making including health warning bracelets. Rapamycin (Sirolimus®), an approved immunosuppressant which also influences autophagy, may prove beneficial. In the interim, while new treatments are developed, a revaluation of cardiac transplantation eligibility criteria is warranted.

Indexed as

AdolescentAdultBiomarkersCardiomyopathy, HypertrophicChildDisease ManagementFemaleGlycogen Storage Disease Type IIbHumansMalePedigreePrognosisTroponin IBiomarkersTroponin IAutophagyDanon diseaseHypertrophic cardiomyopathyLAMP2Learning difficultiesObesityRapamycinThyrotoxicosisTroponin

Identifiers

PMID28822614
PMCPMC6588538
OpenAlexW2657410293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.